226 related articles for article (PubMed ID: 36532027)
1. Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
Alluqmani N; Jirovec A; Taha Z; Varette O; Chen A; Serrano D; Maznyi G; Khan S; Forbes NE; Arulanandam R; Auer RC; Diallo JS
Front Immunol; 2022; 13():1032356. PubMed ID: 36532027
[TBL] [Abstract][Full Text] [Related]
2. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
[TBL] [Abstract][Full Text] [Related]
3. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
4. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.
Olagnier D; Lababidi RR; Hadj SB; Sze A; Liu Y; Naidu SD; Ferrari M; Jiang Y; Chiang C; Beljanski V; Goulet ML; Knatko EV; Dinkova-Kostova AT; Hiscott J; Lin R
Mol Ther; 2017 Aug; 25(8):1900-1916. PubMed ID: 28527723
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
6. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.
Xiao J; Liang J; Fan J; Hou P; Li X; Zhang H; Li K; Bu L; Li P; He M; Zhong Y; Guo L; Jia P; Xiao Q; Wu J; Peng H; Li C; Xing F; Guo D
Cancer Res; 2022 Sep; 82(18):3359-3374. PubMed ID: 35792620
[TBL] [Abstract][Full Text] [Related]
8. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
9. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Kurmasheva N; Said A; Wong B; Kinderman P; Han X; Rahimic AHF; Kress A; Carter-Timofte ME; Holm E; van der Horst D; Kollmann CF; Liu Z; Wang C; Hoang HD; Kovalenko E; Chrysopoulou M; Twayana KS; Ottosen RN; Svenningsen EB; Begnini F; Kiib AE; Kromm FEH; Weiss HJ; Di Carlo D; Muscolini M; Higgins M; van der Heijden M; Bardoul A; Tong T; Ozsvar A; Hou WH; Schack VR; Holm CK; Zheng Y; Ruzek M; Kalucka J; de la Vega L; Elgaher WAM; Korshoej AR; Lin R; Hiscott J; Poulsen TB; O'Neill LA; Roy DG; Rinschen MM; van Montfoort N; Diallo JS; Farin HF; Alain T; Olagnier D
Nat Commun; 2024 May; 15(1):4096. PubMed ID: 38750019
[TBL] [Abstract][Full Text] [Related]
10. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
14. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
16. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Nguyen HM; Guz-Montgomery K; Saha D
Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
[TBL] [Abstract][Full Text] [Related]
18. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
19. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
20. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
